PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

Benign or Malignant? No Way to Tell Radiologically

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Latest News

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

More Evidence Ties Microplastics to Lung Cancer

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

9/11's Latest Wave of Cancers, 25 Years On

Study Warns on Venetoclax in Double-Hit Lymphoma

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Recommended News For You

Scientists discover the 'roadmap' that aggressive cancer uses to spread

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

Could the Prostate Cancer Story of Francis Collins Dissuade Men from Active Surveillance?

Veterans of the Navy have high lung cancer rates associated with asbestos use.

mRNA-based COVID vaccines generate improved responses to immunotherapy

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

Recommended Articles For You

All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology

Targeted Protein Degraders for Previously Undruggable Oncogenic Proteins

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.